Findings of a trial could lead to a new treatment approach for oesophageal cancer.
A new study sheds new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer.
A multi-institutional, randomized phase III trial of fractionation in locally advanced head and neck cancer demonstrated improved local-regional control and improved overall survival with no increase in late toxicity with hyperfractionated radiation therapy.
In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy were cancer-free 28 months after treatment. Side effects typical of standard radiation were also reduced in some cases.
A team of clinicians proposed a virtual navigation system that would allow patients to follow the same pathway as clinic patients but without the formal clinic setting.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|